Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to ...

Wall Street is coming off a losing session after the Federal Reserve paused its interest rate-cutting campaign, leaving its ...

Generally, Zepbound starter doses will be the lowest dose available. You will then gradually increase it if necessary. There is also an FDA box warning for thyroid C-cell tumors for this medication.

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's (LLY) tirzepatide, which is marketed for diabetes as Mounjaro and for weight loss as Zepbound.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Robert F. Kennedy Jr., if confirmed as HHS secretary, could help food-as-medicine startups expand with wider government ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...